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Abstract 
Proteomics has been widely used in the last few years to look for new biomarkers and decipher the mechanism of 
HIV–host interaction. Herein, we review the recent developments of HIV/AIDS proteomic research, including the 
samples used in HIV/AIDS related research, the technologies used for proteomic study, the diagnosis biomarkers 
of HIV-associated disease especially HIV-associated neurocognitive impairment, the mechanisms of HIV–host 
interaction, HIV-associated dementia, substance abuse, and so on. In the end of this review, we also give some 
prospects about the limitation and future improvement of HIV/AIDS proteomic research. 
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Introduction  
Human immunodeficiency virus (HIV) is recognized 
to be one of the most destructive pandemics in re-
corded history. Effective highly active antiretroviral 
therapy and the availability of genetic screening of 
patient virus data have led to sustained viral suppres-
sion and higher life expectancy in patients who have 
been infected with HIV. However, due to the com-
plexity of HIV infection, virus mutation and drug re-
sistance, the knowledge of HIV infection, HIV-associated 
disease, as well as the treatment of these diseases is 
very limited. Despite the massive amount of scientific 
data have been obtained via genomics, additional 
methodologies are needed to help understanding these 
diseases and to provide novel methods for diagnosis 
         
*Corresponding authors. 
E-mail: zhanglijun1221@163.com; hhzhou@public.cs.hn.cn 
© 2010 Beijing Institute of Genomics. 
and treatment. Proteomics is one such methodology 
that is increasingly being used as a tool to study a va-
riety of disease states. As reviewed by List et al (1), 
proteomics has been widely used to study infection 
diseases, including for biomarkers of HIV-induced 
neurocognitive impairment through surface-enhanced 
laser desorption/ionization mass spectrometry (SELDI- 
MS), matrix-assisted laser desorption/ionization mass  
spectrometry (MALDI- MS) technologies, and protein  
arrays for immune response in HIV-infected patients.  
Proteomics has also been used to decipher the  
complex mechanisms in neurodegenerative diseases  
including HIV-associated neurodegenerative disorder,  
as reviewed by Noorbakhsh et al (2). However, these  
two reviews (1, 2) only partly described the develop-
ment in HIV/AIDS. Furthermore, there are some new 
developments in HIV research after these two reviews. 
So in this review, we systematically summarized the 
HIV-infected host proteomic research in HIV/AIDS, 
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Zhang et al. / Host Proteome Research in HIV Infection 
Genomics Proteomics Bioinformatics 2010 Mar; 8(1): 1-9 2
especially in the last two years (Figure 1). 
 
Figure 1  Illustration of the host proteome research in HIV 
infection. 
 
Samples Used in HIV/AIDS Research 
Clinical samples 
In order to find biomarkers and understand the 
mechanism of HIV infection, many kinds of samples 
have been used for proteomic research, including 
sera/plasma from HIV-infected individuals with or 
without cognitive impairment (CI) (3, 4), cerebrospi-
nal fluid (CSF) (5, 6), brain tissue (6), cell extraction 
(7), monocytes of HIV-infected women (8), lavage 
from sex worker (9), formalin fixed paraffin embed-
ded oral HPV lesions from HIV-positive patients (10), 
and placental macrophages separated from 
HIV-infected patients (11). 
HIV infection cell models 
There are several cell models to imitate HIV infection, 
including human T-lymphocyte cell line PM1 stimu-
lated with C33A-produced virus stocks of the HIV-1 
LAI molecular clone (7), the T-cell line infected by a 
biological clone of HIV-1 (X4 strain) (12), the sepa-
rated placental macrophages and blood borne mono-
cyte-derived macrophages (MDMs) inoculated with 
25 ng of HIV-1BaL per 2×105 cells (11), separated 
CD4 cells from healthy donors stimulated with 
autologous serum for 24 h in the presence of 400 
pg/mL recombinant interleukin-2 (13), and HEK 293T 
cells transfected with pTat and flag NC gene of HIV 
(11).  
For cells that cannot be directly infected, some 
modifications are made. For example, Wang et al (14, 
15) separated neurons, microglia and astrocytes from 
embryonic 18-day-old fetuses of C57BL/6 mice. Then 
vesicular stomatitis virus pseudotyped HIV-1 strain 
YU2 (HIV-1/VSV) was used to circumvent the re-
quired viral/cellular receptors necessary to infect 
mouse cells.  
Monkey models 
Since HIV only infects primates, monkeys are the  
main animals for HIV research. Bonneh-Barkay et al  
(6) obtained a simian immunodeficiency virus  
(SIV)-infection model to study proteins related to  
virus loading through pigtailed macaques Macaca  
nemestrina model. In this model, macaques were in  
age from 74 to 93 months, and were intravenously  
infected with SIVDeltaB670 viral swarm. The time  
of infection varied from 42 to 287 days (6). Pendyala  
et al (5) used another monkey model in which  
Rhesus monkeys Macaca mulatta were infected with  
SIV. 
Subcellular proteome 
The proteins in whole cell or tissue are very complex. 
In order to decrease the complexness and discover 
more low abundant proteins, some researchers focus 
their studies on subcellular proteome, including 
plasma membrane (16, 17), secretome (18), exosome 
(19), mitochondria (20), and so on. 
Proteomics Technologies 
There are three general technology lines, including  
two-dimensional electrophoresis (2DE) or difference  
gel electrophoresis mass spectrometry (DIGE-MS) (7,  
9, 17), surface-enhanced laser desorption/ionization  
time-of-flight mass spectrometry (SELDI-TOF-MS)  
(3, 6), and isobaric tag for relative and absolute quan- 
titation (iTRAQ) labeling (10) followed by liquid  
chromatography (LC) separation and MS identification  
(5). Of these three kinds of technologies, DIGE-MS is  
used mostly, followed by SELDI-TOF-MS. 
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Biomarkers of HIV-associated Disease 
HIV-associated neurocognitive impairment 
HIV-1 penetrates the brain shortly after infection and 
remains there throughout entire disease. Approxi-
mately 50% of infected individuals develop some 
forms of CI ranging from an asymptomatic form di-
agnosed during formal testing to the most severe 
HIV-associated dementia (HAD) leading to death (21). 
In order to uncover biomarkers of HAD, proteomic 
approaches have been widely used. Wiederin et al (3) 
analyzed the sera from HIV-infected individuals with 
or without CI through SELDI-TOF-MS analysis fol-
lowed by weak cation exchange chromatography and 
one-dimensional electrophoresis, and discovered gel-
solin and prealbumin as differentially expressed pro-
teins. Laspiur et al (22) used an integrated proteomic 
platform to assess cerebrospinal fluid protein profiles 
from 50 HIV-1 seropositive Hispanic women, and 
found that macrophage capping protein L-plastin and 
Cu/Zn superoxide dismutase (Cu/Zn SOD) were only 
detected in CSF with CI (22). Another research (8) 
showed a decreased Cu/Zn SOD activity in CSF with 
CI than with asymptomatics and normal cognition. 
Rozek et al. (23) reported that Vitamin D binding 
protein, clusterin, gelsolin, complement C3, procolla-
gen C-endopeptidase enhancer 1, and cystatin C were 
up-regulated in HAD through 2D-DIGE analysis. 
HIV-infected children renal disease 
HIV-infected children usually develop renal disease, 
and have the risk of performing renal biopsies. To 
identify new diagnosis biomarkers, Soler-Garcia et al 
(24) carried out urine proteomic analysis for 
HIV-infected children with renal disease. High urine 
levels of β2-microglobulin and retinol-binding protein 
suggested the presence of tubular injury. Elevated 
urine levels of iron and the iron-related proteins, 
transferrin, hemopexin, haptoglobin, lactoferrin, and 
neutrophil gelatinase-associated lipocalin were also 
found in children with HIV-nephropathy (HIVAN) 
and HIV-associated hemolytic uremic syndrome 
(HIV-HUS). These iron and iron-related proteins 
might be promising candidate urine biomarkers to 
identify HIV-infected children at risk of developing 
HIVAN and HIV-HUS. The release or accumulation 
of iron in the kidney of HIV-infected children may 
contribute to the rapid progression of their renal dis-
ease, and could become a new therapeutic target 
against HIVAN and HIV-HUS. 
Biomarkers related to virus loading 
Detection of virus loading is very expensive although 
it is the gold standard for the prognosis of AIDS. So it 
is very important to develop new biomarkers for re-
placing virus loading. Through proteomic analysis of 
postmortem CSF and brain tissue from the SIV pri-
mate model, Bonneh-Barkay et al (6) found that 
Chitinase-3-like protein 1 (YKL-40) was tightly asso-
ciated with lentiviral encephalitis and up-regulated 
with an increase in CSF viral load. 
Mechanism of HIV Infection 
HIV–host interaction 
HIV-1 interacts through multiple signaling pathways  
to reprogram the transcriptome and the proteome of  
host cells. HIV-1-induced stimulation of macrophages  
is a multi-step process that occurs directly in infected  
cells, as well as indirectly in bystander cells through  
paracrine signaling. Emerging genomic and proteomic  
techniques have elucidated a myriad of cellular genes  
involved in viral replication representing a collection  
of possible new drug targets. For example, in the  
study of Ringrose et al (7), human T cells upon HIV-1  
infection showed that 15% of 2,000 protein spots  
were differentially expressed at peak infection, in 
which 27 proteins were found to be significantly  
down-regulated and 66 were up-regulated at peak  
HIV infection. Early in infection, only a small group  
of proteins were changed. A clear and consistent  
program of metabolic rerouting of HIV causing host  
cell apoptosis through mitochondrial-dependent  
pathway was reported (20). The proteome of apoptotic  
T cells includes prominent fragments of cellular  
proteins generated by caspases. A high proportion of  
distinct T cell epitopes in these fragments is  
recognized by CD8+ T cells during HIV infection.  
The frequencies of effector CD8+ T cells that are  
specific for apoptosis-dependent epitopes correlate  
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with the frequency of circulating apoptotic CD4+ T  
cells in HIV-1-infected individuals (25). Another  
research (17) showed that one functional consequence  
of virus-exposure to the monocyte was the facilitation  
of protein transformation from the cytosol to the  
plasma membrane. HIV-1-induced plasma membrane  
protein translocation was associated with cathepsin 
B- and caspase 9, 3-dependent apoptosis. Furthermore,  
Rasheed et al (12) found that HIV replication alone  
could induce novel cellular enzymes and proteins that  
are significantly associated with biologically relevant  
processes involved in lipid synthesis, transport and  
metabolism. Proteomic research by Pathak et al (26)  
also showed that HIV induces both a down-regulation  
of Interleukin-1 receptor-associated kinase 4 (IRAK-4)  
that impairs Toll-like receptor (TLR) signaling and an  
up-regulation of the antibiotic peptide dermcidin in  
monocytic cells. The decreased immune response 
resulted in HIV-infected individuals with an increased  
risk of invasive bacterial infections, even at early  
clinical stages with relatively normal CD4+ T-cell  
counts. In all, along each step of the viral life cycle,  
viral RNA and proteins encounter as many as 250 host  
cell factors that either facilitate or restrict viral infec- 
tion (27). Dyer et al (28) integrated human–pathogen  
protein–protein interactions (PPIs) for 190 pathogen  
strains from seven public databases. Nearly all of the  
10,477 human–pathogen PPIs are for viral systems  
(98.3%), with the majority belonging to the hu- 
man–HIV system (77.9%). They found that both viral  
and bacterial pathogens tend to interact with hubs  
(proteins with many interacting partners) and bottle- 
necks (proteins that are central to many paths in the  
network) in the human PPI network. 
Apart from these researches considering the whole  
HIV interaction with host cells, there are also many  
studies thinking about the affection of function 
proteins in HIV to host, where the virus proteins also  
strongly influence levels of proteins involved in host  
proteins.  
A quantitative proteomics analysis (29) using the  
plasma membrane fraction of HeLa cells expressing  
either wild-type Vpu or a Vpu mutant (S52N/S56N)  
that does not bind betaTrCP showed that one cellular  
protein, BST-2 (CD317), was consistently underrep- 
resented in the membrane proteome of cells expressing 
wild-type Vpu compared to the proteome of cells 
expressing the Vpu mutant. BST-2 down-regulation  
occurred in a Vpu-dependent manner in the trans-Golgi  
network or in early endosomes, leading to lysosomal  
degradation of BST-2.  
Moreover, proteomics was used to study the inter-
action between the Tat and nucleocapsid proteins (30, 
31). Gautier et al (31) has designed a proteomic 
strategy based on affinity chromatography coupled 
with MS. A total of 183 proteins were identified as Tat 
nuclear partners, 90% of which have not been previ-
ously characterized. These proteins are enriched for 
domains mediating protein, RNA and DNA interac-
tions, as well as helicase and ATPase activities. 
Proteomics was also used to study the interaction 
between HIV-1 viral protein R (Vpr) and host cells. 
For example, He et al (32) infected C8166 cells with a 
recombinant adenovirus carrying both vpr and GFP 
genes (rAd-vpr), as well as the vector control virus 
(rAd-vector), and found apoptosis related protein 
changes, exhibiting the regulation of caspase-3 activ-
ity indicator proteins (vimentin and Rho 
GDP-dissociation inhibitor 2), mitochondrial protein 
(prohibitin) and other regulatory proteins. The 
up-regulation of anti-inflammatory redox protein, thi-
oredoxin, was identified in the rAd-vpr infected group 
and the increase of caspase 3&7 activity in the 
rAd-vpr infected group was observed. Endogenous 
Vpr is able to kill HTLV-1 transformed C8166 cells, 
and may avoid the risks of inducing severe inflam-
matory responses through apoptosis-inducing and 
anti-inflammatory activities.  
Another application of proteomics is to study the 
interaction between HIV-1 viral protein Vpx and host 
cells. Using biochemical and proteomic approaches, 
Srivastava et al (33) found that Vpx protein of the 
pathogenic SIVmac 239 strain associates with a ter-
nary protein complex comprising DDB1 and VprBP 
subunits of Cullin 4-based E3 ubiquitin ligase, and 
DDA1, which has been implicated in the regulation of 
E3 catalytic activity, and that Vpx participates in the 
Cullin 4 E3 complex comprising VprBP. 
HIV-associated dementia (HAD) 
Despite the availability of highly active antiretroviral 
therapy, HAD continues to affect approximately 10% 
of AIDS patients usually in the later stages of disease. 
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HIV-1-associated neurocognitive disorder (HAND) is 
a complication marked by cognitive, behavioral, and 
motor dysfunction that develops during the later 
stages of AIDS. The pathological hallmarks of HAND 
are characterized by microglia cell activation, astro-
cytosis, decreased synaptic function, leukocyte infil-
tration, multinucleated giant cells and selective neu-
ronal loss. Microglia/macrophages are the most 
commonly infected cells in the brain and serve as 
lifelong hosts for HIV. Microglial HIV infection and 
viral replication result in the secretion of neurotoxic 
pro-inflammatory cytokines, chemokines and viral 
proteins that strongly implicate microglia hy-
per-activation in the progression of HAND. So far, 
most research showed that the cardinal neuropa-
thological features of HAD are represented by multi-
nucleated giant cells, viral antigens and genomes in 
macrophages and microglia, diffuse myelin pallor, 
microglial nodules and synapto-dendritic pruning with 
neuronal loss (34). As reviewed by Noorbakhsh et al 
(2), two main mechanisms have been considered in 
the neuropathogenesis of HAD: (1) HIV-encoded 
proteins, including gp120, Tat and Vpr, released by 
infected monocytoid cells exert direct neurotoxic ef-
fects (35, 36); (2) activated macrophages, microglia 
and astrocytes produce multiple host proinflammatory 
molecules and neurotoxins that contribute to neuronal 
dysfunction and death (35, 36). 
HAD-descriptive analyses uncovered inflammation 
mechanism in patients 
Comparison of the CSF proteome of HAD with 
non-demented HIV/AIDS patients shows altered lev-
els of proteins related to cell signaling and the com-
plement pathway related to inflammation in HAD 
patients (2, 22, 23, 37). For example, Toro-Nieves et 
al (37) hypothesize that neurovirulent HIV-1 variants 
affect the mononuclear phagocytes proteome by in-
ducing a signature of neurotoxic proteins and thus 
affect cognitive function. To test this hypothesis, they 
used HIV-1 separated from normal cognition (NC) 
and CI, and the laboratory adapted SF162 (a spinal 
fluid R5 isolate from a patient with HIV-1-associated 
dementia) to infect MDMs. As a result, 6 unique pro-
teins in NC, 7 in SF162, and 20 in CI were identified. 
Three proteins were common to SF162 and CI strains. 
The MDM proteins linked to infection with CI strains 
were related to apoptosis, chemotaxis, inflammation 
and redox metabolism. 
HAD was found to be involved in oxidative stress 
Proteomic approaches have highlighted the involve-
ment of oxidative-stress pathways in HIV-induced 
neurological injury. Proteins targeted by oxidative 
modification have been detected in neural cells ex-
posed to HIV proteins. Proteomic analysis of 
HIV-infected microglia has shown altered levels of 
redox enzymes (14). Altered antioxidant activity in 
addition to altered vitamin-D-metabolism-related en-
zymes have been identified by proteomic analysis of 
CSF from HAD and non-demented HIV/AIDS pa-
tients (22, 23). 
HIV altered brain microenvironment 
Similar to other neuroinflammatory conditions, pro-
teomic analysis of CSF from HIV-infected patients 
with CI has shown dysregulation of protease inhibi-
tors (i.e., clusterin and cystatin C), enzymes involved 
in metabolism and also proteins involved in 
blood–brain-barrier function (23, 38). HIV-1-infected 
MDMs affect the human brain microvascular endo-
thelial cell (HBMEC) proteome (38). These MDMs 
induced the up-regulation of over 200 HBMEC pro-
teins, including metabolic, voltage-gated ion channels, 
heat shock, transport, cytoskeletal, regulatory, and 
calcium-binding proteins. HIV-1-infected MDMs af-
fect the HBMEC proteome and, in this way, affect 
blood–brain-barrier dysfunction and the development 
of HIV-1 CNS disease (38). 
Proteomics was used to discover how the commu-
nication of astrocytes with macrophages and micro-
glia can influence disease (14). Using vesicular 
stomatitis virus pseudotyped HIV-infected murine 
microglia, Wang et al (14) found 68 differentially ex-
pressed proteins involved in cell structure, regulation, 
etc., and demonstrated that astrocytes and microglial 
interaction probably accelerated cell death and in-
creased the development of HAD through these pro-
teins. At the same time, they found that infected as-
trocytes showed modest changes in protein elements 
as compared to uninfected cells through co-culture 
systems of HIV-infected mouse astrocytes and micro-
glia (15). Similarly, another proteomic study (39) of 
isolated nerve endings from 19 human brain speci-
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mens showed that the concentrations of 31 candidate 
protein spots were potentially abnormal in 
HIV-infected decedents with HIV encephalitis and/or 
increased expression of immunoproteasome (IPS) 
subunits. Synapsin 1b and stathmin were inversely 
related to brain HIV-1 load; 14-3-3ζ and 14-4-4ε pro-
teins were higher in subjects with HIV-1 loads. Per-
turbed synaptosome proteins were linked with IPS 
subunit composition, and 14-3-3ζ was histologically 
colocalized with IPS subunits in stained neocortical 
neurons. 
Protecting mechanism of HIV infection 
Mechanism of HIV resistance in sex workers 
In HIV-resistant sex workers who are highly exposed 
to HIV infection yet remain uninfected, the identifica-
tion of natural factors involved in protection against 
HIV-1 in the genital mucosa has caused great interest 
in the development of mucosal HIV-1 microbicides. 
The genital proteome of mucosal secretions from 
HIV-resistant women was examined by Iqbal et al 
(40). Through SELDI-MS analysis of the mucosa 
from 315 HIV-resistant, HIV-uninfected and 
HIV-infected commercial sex workers, elevated ela-
fin/trappin-2 in the female genital tract was found to 
be associated with protection against HIV acquisition. 
Another study (9) using quantitative proteomics tech-
nique of 2D-DIGE combined with MS showed that 
over 15 proteins were differentially expressed be-
tween HIV-1-resistant women and control groups, 
including the overexpressed serpin B family, and also 
cystatin A, a known anti-HIV-1 factor. 
Mechanism of placenta protecting the fetus 
Mononuclear phagocytes (MP; monocytes, tissue 
macrophages and dendritic cells) are reservoirs, vehi-
cles of dissemination, and targets for persistent HIV 
infection. However, not all MP population equally 
supports viral growth. Such differential replication is 
typified by the greater ability of placental acrophages 
(PM), as compared to blood borne MDM, to restrict 
viral replication (41). Luciano-Montalvo et al (41) 
used a proteomics approach consisting of SELDI-TOF, 
tandem mass spectrometry and Western blots to iden-
tify differences between the uninfected and 
HIV-infected PM and MDM protein profiles linked to 
viral growth. The results demonstrate that the low 
molecular weight placental macrophage cytosolic 
proteins are differentially expressed in HIV-infected 
PM and MDM and identify a potential role for cys-
tatin B in HIV replication. This work also serves to 
elucidate a mechanism by which the placenta protects 
the fetus from HIV transmission. 
Mechanism of immune system responding to 
pathogens associated with substance abuse 
Substance abuse has become a global health concern. 
Understanding how substance abuse modulates the 
immune system and how the immune system responds 
to pathogens associated with substance abuse, such as 
hepatitis C virus (HCV) and HIV-1, can be assessed 
by an integrated approach combining proteomic 
analyses and quantification of gene expression (42, 
43). When monocyte-derived mature dendritic cells 
(DC) were treated with cocaine or methamphetamine, 
the protein expression of DC was significantly 
changed, including several functional classes of pro-
teins such as those that modulate apoptosis, protein 
folding, protein kinase activity and metabolism as 
well as proteins that function as intracellular signal 
transduction molecules (42). The proteome of periph-
eral blood mononuclear cells isolated from 
HIV-1-positive donors that occurred after treatment 
with cocaine or methamphetamine also showed that 
both drugs differentially regulated the expression of 
several functional classes of proteins in monocytes 
and T cells (43). 
Future Prospects 
In the host proteome research reviewed herein, de-
scriptive studies have pointed to biomarker discovery, 
infection mechanism, protecting mechanism of HIV 
infection, and immune system responding to patho-
gens associated with substance abuse. Although many 
progresses have been made in HIV/AIDS research 
through genomics, the advent of proteomics has been 
greatly broadening our view and accelerating our way 
in HIV/AIDS research fields. By jointly using ge-
nomics, proteomics and bioinformatics, there is a 
great potential to make considerable contribution to 
biomarker identification and to revolutionize both the 
development of new therapies and drug development 
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process. However, the power of applying proteomics 
in understanding HIV/AIDS would be enhanced in the 
follows: (1) Human tissues available from autopsies 
chiefly reflect molecular changes related to the late 
stages of disease – a drawback to most descriptive 
studies on human tissues. More cells or animal mod-
els to imitate the HIV infection process are needed. So 
far, most researches use non-human primate animals 
(5, 6, 44) due to HIV infection characters. However, 
the primate animals are very expensive and difficult to 
obtain, therefore more animals that are easy to obtain 
and cheap to feed are needed. Luckily, mouse (45, 46) 
or rat (47, 48) models with trans-HIV genes have been 
developed and might be used to HIV infection re-
search. It will be better to use these models for 
HIV–host interaction research and drug development. 
(2) Another issue facing descriptive analyses is the 
lack of “spatial” resolution. In whole-tissue extrac-
tions, the opportunity to examine an important level 
of biocomplexity (i.e., cell-specific expression of 
biomolecules) is lost. Therefore it is very important to 
develop more proteomic technologies for cell-specific 
proteomic studies. At present, different kinds of cells 
can be well separated through Flow Cytometer (49, 
50). It will bring great progress to “spatial” resolution 
in proteomics if the cells separated by Flow Cytome-
ter can be used in proteome study. Furthermore, 2D or 
3D cell grow systems have been developed to study 
cell–cell interaction (51), and have great potential in 
proteomic research. In whole-cell extraction, the pro-
teins with low abundance might be lost due to the 
overlap of high abundant proteins. In order to solve 
this question, subcellular proteomic technology, im-
muno-purification, fractionation and different protein 
separation technologies have been developed (52). (3) 
The dynamical protein changes were not considered 
in most of researches. Modeling the dynamical be-
havior of the networks using data derived from inte-
grated analyses, coupled with descriptive studies with 
a temporal resolution, will be the best strategy to un-
derstand, predict and modify the disease course for 
HIV infection. To solve dynamical protein changes, 
many researchers have focused on multiple reaction 
monitoring (MRM) (53), which can simultaneously 
quantify nearly 500 ion-pairs with 50 copies/cell in 
several minutes. (4) The reports about protein 
post-translational modification (PTM) such as phos- 
pholation and glycosylation in HIV/AIDS were very  
limited. It is very inadequate for PTM studies since  
many functions of proteins are carried through PTM.  
So far only one glycoproteomic study reports HIV to  
uncover host proteins involved in virus (54). (5) 
Further research for discovering protein functions is  
very limited. Most of the studies only reported the  
differently expressed proteins. No data about the rela- 
tionship between the different proteins and virus. (6)  
The application of proteomics in HIV/AIDS is very  
limited and neglected. During the past several years,  
proteomics has developed many new technologies  
such as iTRAQ/ICAT-LC-MS (55, 56), MRM (53),  
and Protein Chip or array technology (57). These new  
technologies have been widely used in cancer re- 
search (55, 57). Furthermore, genomics, proteomics  
and bioinformatics have been jointly used to deeply  
discover drug targets, biomarkers (58, 59), or evaluate  
vaccine and immune response (60, 61); however, so  
far only few studies were reported in HIV/AIDS (62).  
Summarily, proteomics is a very useful tool for  
HIV/AIDS research, but needs to be improved in sev- 
eral aspects such as spatial, dynamic, low abundant  
protein information.  
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